Related Experiment Video
Updated: May 13, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
Growth factor independence 1 (Gfi1) as a regulator of p53 activity and a new therapeutical target for ALL
Cyrus Khandanpour1, Tarik Möröy
1Department of Hematology, Universitätsklinikum Essen, Essen, Germany. Cyrus.Khandanpour@uk-essen.de
Abstract:
The transcriptional repressor Gfi1 can be a so-called "oncorequisite" factor that is required for the development and maintenance of lymphoid neoplasia, such as Acute Lymphoblastic Leukemia (ALL), but does not have a direct role in the ontogeny of the disease. The study supporting this role of Gfi1 (Khandanpour C, Phelan J, et al., Cancer Cell, 2013, 23:200-214) shows that inhibition of Gfi1 cannot only cure mice from ALL but also blocks the expansion of human primary ALL cells. The study concludes that this feature of Gfi1 can be exploited to improve current ALL therapies.
Insights
The transcriptional repressor Gfi1 is crucial for maintaining lymphoid cancers like Acute Lymphoblastic Leukemia (ALL). Inhibiting Gfi1 cures ALL in mice and halts human ALL cell growth, offering a new therapeutic strategy.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Gfi1 (Growth factor independent 1) is a transcriptional repressor.
- Gfi1 acts as an "oncorequisite" factor in lymphoid neoplasia, including Acute Lymphoblastic Leukemia (ALL).
- Gfi1 is essential for the maintenance of lymphoid cancers but not their initial development.
Purpose of the Study:
- To investigate the role of Gfi1 in the development and maintenance of lymphoid neoplasia.
- To evaluate the therapeutic potential of inhibiting Gfi1 in ALL models.
Main Methods:
- The study utilized mouse models of ALL and human primary ALL cells.
- Inhibition of Gfi1 was employed as a therapeutic strategy.
Main Results:
- Inhibition of Gfi1 successfully cured mice with ALL.
- Gfi1 inhibition effectively blocked the proliferation of human primary ALL cells.
- Gfi1 was confirmed as an "oncorequisite" factor, necessary for sustaining the disease.
Conclusions:
- Gfi1 plays a critical role in maintaining lymphoid cancers like ALL.
- Targeting Gfi1 presents a promising therapeutic avenue for improving ALL treatment.
- The findings suggest Gfi1 inhibition can be a valuable addition to current ALL therapies.
Related Concept Videos
Negative Regulator Molecules
Abnormal Proliferation
GTPases and their Regulation
Large G-proteins, also known...
GTPases and their Regulation
Large G-proteins, also known...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Regulation of Angiogenesis and Blood Supply